• Categories:P7仿制药
• Author:
• Origin:
• Time of issue:2021-11-20
• Views:0

(Summary description)<h3>Focus on elderly Parkinson's disease</h3>

<table class="res_table">
<thead>
<tr>
<th>Function</th>
<th>Drug</th>
<th>Dosage form</th>
<th>Treatment</th>
</tr>
</thead>

<tbody>
<tr>
<td data-title="Function">GABA receptor</td>
<td data-title="Drug">Stiripentol</td>
<td data-title="Dosage form">Suspension</td>
<td data-title="Treatment">Anticonvulsant drugs for epilepsy, Dravet syndrome</td>
</tr>
<tr>
<td data-title="Function">
<span>Voltage-gated Na+ channels selectively enhance the slow inactivation of voltage-gated sodium channels</span>
</td>
<td data-title="Drug">Lacosamide</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Adjuvant treatment of partial seizures with or without secondary full-blown seizures</td>
</tr>
<tr>
<td data-title="Function">Dopamine and serotonin receptor antagonists</td>
<td data-title="Drug">Blonanserin</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Schizophrenia</td>
</tr>
<tr>
<td data-title="Function">Dopamine and serotonin receptor antagonists</td>
<td data-title="Drug">Lurasidone</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Schizophrenia and bipolar depression</td>
</tr>
<tr>
<td data-title="Function">Levodopa + benserazide compound preparation</td>
<td data-title="Drug">Levodopa and Benserazide</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Parkinson's disease, symptomatic Parkinson's syndrome</td>
</tr>
<tr>
<td data-title="Function">Catechol-O-methyltransferase (COMT) inhibitor</td>
<td data-title="Drug">Entacarbon and Compound</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Adjunctive use of levodopa/benserazide or levodopa/carbidopa</td>
</tr>
<tr>
<td data-title="Function">Monoamine oxidase type B(MAO-B) inhibitors</td>
<td data-title="Drug">Safinamide</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Adjunctive therapy of levodopa/carbidopa in Parkinson's disease</td>
</tr>
<tr>
<td data-title="Function">Monoamine oxidase type B(MAO-B) inhibitors</td>
<td data-title="Drug">Rasagiline</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Monotherapy for primary Parkinson's disease, combined therapy with end-dose fluctuations</td>
</tr>
<tr>
<td data-title="Function">5-HT1A. 5-HT1B agonist, 5-HT3', 5HT1D, 5-HT7 receptor antagonist</td>
<td data-title="Drug">Vortioxetine</td>
<td data-title="Dosage form">Tablets</td>
<td data-title="Treatment">Major depression</td>
</tr>
</tbody>
</table>